文献速递淋巴瘤

3期POLARIX研究中≥60岁弥漫大B细胞淋巴瘤老年患者的亚组分析

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.
PubMed 文献 · Blood Adv · 2025-01-01

该研究为3期POLARIX的事后亚组分析,评估Pola-R-CHP对比R-CHOP在≥60岁初治弥漫大B细胞淋巴瘤患者中的疗效与安全性。截至2022年6月15日(中位随访40个月),纳入629例≥60岁患者(Pola-R-CHP组311例,R-CHOP组318例)。各年龄组Pola-R-CHP均显示具有临床意义的PFS改善,≥70岁患者疾病进展、复发或死亡风险降低37%(未分层HR 0.63,95%CI 0.41-0.96);安全性特征相似,但Pola-R-CHP组3-4级发热性中性粒细胞减少发生率更高(16.3% vs 7.6%)。

要点

  • ≥70岁患者中Pola-R-CHP较R-CHOP降低疾病进展、复发或死亡风险37%(未分层HR 0.63,95%CI 0.41-0.96)。
  • Pola-R-CHP组3-4级发热性中性粒细胞减少发生率16.3% vs R-CHOP组7.6%,提示需重视G-CSF预防。

核心结论

  • 在≥60岁初治弥漫大B细胞淋巴瘤老年患者中,Pola-R-CHP对比R-CHOP的获益-风险特征更有利。

研究设计与样本

  • 3期POLARIX研究的事后亚组分析,评估Pola-R-CHP对比R-CHOP在≥60、≥65、≥70和≥75岁初治弥漫大B细胞淋巴瘤患者中的疗效与安全性。
  • 截至2022年6月15日(中位随访40个月),纳入629例≥60岁患者(Pola-R-CHP组311例,R-CHOP组318例)。

主要发现

  • 各年龄组Pola-R-CHP对比R-CHOP均观察到具有临床意义的PFS改善,尤其在≥70岁患者中疾病进展、复发或死亡风险降低37%(未分层HR 0.63,95%CI 0.41-0.96)。
  • ≥60岁患者中Pola-R-CHP对比R-CHOP安全性特征相似:3-4级不良事件发生率62.7% vs 61.5%,3-5级感染15.0% vs 12.9%,5级不良事件3.6% vs 3.2%,未报告新的毒性。
  • ≥60岁患者中Pola-R-CHP对比R-CHOP的3-4级发热性中性粒细胞减少发生率更高(16.3% vs 7.6%)。

临床怎么用

  • 作者指出,在接受Pola-R-CHP的老年患者中,粒细胞集落刺激因子预防具有重要性。
  • 在≥60岁初治弥漫大B细胞淋巴瘤老年患者中,Pola-R-CHP对比R-CHOP的获益-风险特征更有利。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 POLARIX study, Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) improved progression-free survival (PFS) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This post hoc subgroup analysis of POLARIX evaluated the efficacy and safety of Pola-R-CHP vs R-CHOP in older patients aged ≥60, ≥65, ≥70, and ≥75 years. As of 15 June 2022 (median follow-up, 40 months), 629 patients aged ≥60 years were included (Pola-R-CHP, n = 311; R-CHOP, n = 318). Clinically meaningful improvements in PFS with Pola-R-CHP vs R-CHOP were observed across all age groups, particularly in patients aged ≥70 years whereby the risk of disease progression, relapse, or death was reduced by 37% (unstratified hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.96). In patients aged ≥60 years, overall survival was similar with Pola-R-CHP vs R-CHOP (unstratified HR, 0. 99; 95% CI, 0.67-1.47). Safety profiles were similar for Pola-R-CHP vs R-CHOP among patients aged ≥60 years, including rates of grade 3 to 4 adverse events (AEs; 62.7% vs 61.5%), grade 3 to 5 infections (15.0% vs 12.9%), and grade 5 AEs (3.6% vs 3.2%); no novel toxicities were reported. Incidence of grade 3 to 4 febrile neutropenia was higher with Pola-R-CHP than R-CHOP (16.3% vs 7.6%), highlighting the importance of granulocyte colony-stimulating factor prophylaxis in older patients receiving Pola-R-CHP. The benefit-risk profile favored Pola-R-CHP vs R-CHOP in older patients with previously untreated DLBCL. This trial was registered at www.ClinicalTrials.gov as #NCT03274492.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hu B, Reagan PM, Sehn LH, et al. Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025. PMID: 40085955. doi:10.1182/bloodadvances.2024014707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。